title: Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances.
abstract: OBJECTIVE
  Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are gastrointestinal peptides that play an important role as incretin hormones in the regulation of plasma glucose and insulin secretion. GLP-1-based therapies have therefore been implemented as treatment for type 2 diabetes (T2D). The purpose of this review is to summarize novel treatment options for T2D with GLP-1-based therapies. In addition, both peptides have relevant extrapancreatic effects that have been further characterized recently and are summarized in this review.
  
  
  RESULTS
  Novel findings regarding changes in GLP-1 secretion after bariatric surgery are highlighted, wherein GLP-1 plays a role in promoting body weight loss and diabetes remission. For T2D therapy, novel options with long-acting GLP-1 analogs are summarized that show a good efficacy and safety profile, also in combination with insulin as well as for obesity treatment. As GIP is not suitable for T2D therapy, extrapancreatic effects of GIP, mainly on bone metabolism that have been characterized recently, are described. These show that the activated GIP receptor is important to allow optimal bone mass and structure.
  
  
  CONCLUSIONS
  This review summarizes new findings on the physiology and pathophysiology of GLP-1 and GIP and novel therapeutic aspects.
authors.affiliation: Department of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, Germany.
authors.forename: Baptist
authors.initials: B
authors.lastname: Gallwitz
mesh_terms: D006801:Humans; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1